2950 Progabide Progabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. Progabide has been investigated for many diseases besides epilepsy, including Parkinson's disease, schizophrenia, clinical depression and anxiety disorder with varying success. 62666-20-0 5361323 C17H16ClFN2O2 334.088430 White powder. 133-135°C 70.9 mg/L Well absorbed with a bioavailability of 60% Progabide binds to both GABA_A and GABA_B receptors located on the terminals of primary afferent fibers. Binding to GABA_A results in an increased affinity of the GABA receptor for the amino acid, an augmented flux of chloride ions across the terminal membrane, and an increase in the amount of presynaptic inhibition. Activation of the GABA_B receptors retards the influx of calcium ions into the terminals, thereby reducing the evoked release of excitatory amino acids and possibly other transmitters. Hepatic Half Life: 4 hours No indication of carcinogenicity to humans (not listed by IARC). Indicated for the treatment of epilepsy. May cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease. 2009-07-21T20:27:47Z 2014-12-24T20:25:53Z Progabide Progabide DB00837 true OC(=N)CCCN\C(C1=CC=C(Cl)C=C1)=C1/C=C(F)C=CC1=O C17H16ClFN2O2 InChI=1S/C17H16ClFN2O2/c18-12-5-3-11(4-6-12)17(21-9-1-2-16(20)23)14-10-13(19)7-8-15(14)22/h3-8,10,21H,1-2,9H2,(H2,20,23)/b17-14+ InChIKey=DWEQWXSKOHHBNT-SAPNQHFASA-N 334.773 334.088433678 Exogenous Solid 3.06 HMDB14975 CHEMBL287631 4514729